A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. (2023)
Attributed to:
Development of Metabolism Radiotracers to Probe Disease Pathology in Human Subjects with Cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jtho.2023.01.089
PubMed Identifier: 36773776
Publication URI: http://europepmc.org/abstract/MED/36773776
Type: Journal Article/Review
Volume: 18
Parent Publication: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Issue: 6
ISSN: 1556-0864